Representative Pete Sessions reported selling AbbVie shares on Sept 14 in a filing that lists the sale's value between $30,002 and $100,000. The article says sales can reflect many personal reasons, so this disclosure does not change AbbVie's business outlook.
The disclosed sale by a congressman is a personal transaction and does not change AbbVie's drugs, cash, or clinical results. The article itself warns that sales can reflect many personal reasons, so the company's business picture stays the same.
Representative Pete Sessions reported selling Alphabet shares on Sept 14 with a reported value of $15,001-$50,000. The piece notes such sales can reflect personal reasons, so the company's business view is unchanged.
The filing shows a small Ares Capital sale of $1,001-$15,000 on July 24. Given the small size and disclosure rules, this does not change Ares Capital's business outlook.
Follow AbbVie (ABBV) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for ABBV